Sakar Healthcare shares hit an intraday high of Rs 1,034.10 on Oct 14 after starting commercial cancer drug supplies from an EU GMP unit.

Sakar Healthcare Ltd said commercial supplies have begun from its EU GMP-certified facility.

EU GMP is the quality standard Europe uses to judge how medicines are made, so it opens the door to regulated markets. The company focuses on cancer medicines, known as oncology drugs.

Put another way, a factory with that certificate can supply medicines to European buyers, not just Indian ones.

The company also said 22 of its 190 applications for marketing approval have been cleared so far. Price caps on cancer drugs in India, it added, are not expected to affect its operations.

Reports of the announcement do not say how large the first shipments are or where they will go.

The latest results cover April to June 2026. Revenue from operations rose 38% to Rs 72.97 crore from Rs 52.73 crore a year earlier. Net profit climbed 120% to Rs 10.28 crore from Rs 4.67 crore.

In September 2026, Sakar won 14 new cancer drug approvals across the EU, UK and Canada, working with seven business partners.

In May, it signed a supply agreement with Zydus Lifesciences covering Gulf countries and other emerging markets.

Sakar Healthcare closed at Rs 1,020.80 on NSE, up by Rs 69.20 or 7.27%. Around 1.90 lakh shares changed hands, worth Rs 18.99 crore. The Nifty 50 ended 0.44% lower.

The stock is up 181.39% over the past year and 150.31% so far this year, though it is down 12.09% over the past month.

Its 52-week high of Rs 1,229.85 came on 23 September, and its market value is about Rs 2,271 crore.

Ready to invest like a pro? Tradz by EquityPandit app equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz by EquityPandit app and gain access to daily stock lists and insightful market analysis and much more!